Novo Nordisk’s Blockbuster Drug Fails To Slow Alzheimer’s Disease Progression In Studies
Synopsis
The company said that it is discontinuing the trials.
Novo Nordisk on Monday said that its late-stage trials evaluating Semaglutide in Alzheimer’s disease did not confirm its superiority over placebo in slowing disease progression.
Shares of the company fell over 9% in the pre-market session at the time of writing.
Semaglutide is the active ingredient in Novo’s blockbuster weight-loss drug Wegovy. The company said that it decided to test the drug in Alzheimer’s based on real-world evidence studies, pre-clinical models, as well as post-hoc analyses from diabetes and obesity trials.
The company conducted two late-stage studies, and while an improvement of Alzheimer’s disease-related biomarkers was observed in both trials with Semaglutide, it did not delay the progression of the disease, the company said.
The company said that it is discontinuing the trials.
Get updates to this developing story directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.